RubenAMesaMDFACP

PubMed

• The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence.
  Mendez Luque, L., Avelar-Barragan, J., Nguyen, H., Nguyen, J., Soyfer, E., Liu, J., Chen, J., Mehrotra, N., Huang, X., Kosiorek, H., Dueck, A., Himstead, A., Heide, E....> ;Cancer Research Communications. 2024 Mar 5
• 1 citations
  Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.
  Hudgens, S., Verstovsek, S., Floden, L., Harrison, C., Palmer, J., Gupta, V., McLornan, D., McMullin, M., Kiladjian, J., Foltz, L., Platzbecker, U., Fox, M., Mead, A.,...> ;Value in Health. 2024 Feb 2
• A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase...
  Verstovsek, S., Talpaz, M., Wadleigh, M., Isidori, A., Te Boekhorst, P., Savona, M., Bose, P., Pozdnyakova, O., Mesa, R., El-Galaly, T., O'Sullivan, J., Gamel, K., Hig...> ;Haematologica. 2024 Jan 25
• Interferons in the treatment of myeloproliferative neoplasms.
  Pankit Vachhani, John Mascarenhas, Prithviraj Bose, Gabriela Hobbs, Abdulraheem Yacoub, Jeanne M Palmer, Aaron T Gerds, Lucia Masarova, Andrew T Kuykendall, Raajit K R...> ;Therapeutic Advances in Hematology. 2024 Jan 1
• 1 citations
  Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group.
  Kröger, N., Bacigalupo, A., Barbui, T., Ditschkowski, M., Gagelmann, N., Griesshammer, M., Gupta, V., Hamad, N., Harrison, C., Hernandez-Boluda, J., Koschmieder, S., J...> ;The Lancet. Haematology. 2024 Jan 1
• 2 citations
  Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.
  Jean-Jacques Kiladjian, Alessandro M Vannucchi, Aaron T Gerds, Vikas Gupta, Srdan Verstovsek, Miklos Egyed, Uwe Platzbecker, Jiří Mayer, Sebastian Grosicki, Árpád Illé...> ;Hemasphere. 2023 Nov 1
• 2 citations
  Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study.
  Ruben A Mesa, Claire Harrison, Jeanne M Palmer, Vikas Gupta, Donal P McLornan, Mary Frances McMullin, Jean-Jacques Kiladjian, Lynda Foltz, Uwe Platzbecker, Maria Laura...> ;Hemasphere. 2023 Nov 1
• 24 citations
  Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.
  Stephen T Oh, Ruben A Mesa, Claire N Harrison, Prithviraj Bose, Aaron T Gerds, Vikas Gupta, Bart L Scott, Jean-Jacques Kiladjian, Alessandro Lucchesi, Tim Kong, Sarah ...> ;Blood Advances. 2023 Oct 10
• 2 citations
  Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an interna...
  Aaron T Gerds, Srdan Verstovsek, Alessandro M Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew T Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mi...> ;The Lancet. Haematology. 2023 Sep 1
• 2 citations
  Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
  Srdan Verstovsek, Ruben A Mesa, Robert A Livingston, Wilson Hu, John Mascarenhas> ;Journal of Hematology & Oncology. 2023 Jul 27
• 1 citations
  A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis.
  John Mascarenhas, Anna Rita Migliaccio, Heidi Kosiorek, Rupali Bhave, Jeanne Palmer, Andrew Kuykendall, Ruben Mesa, Raajit K Rampal, Aaron T Gerds, Abdulraheem Yacoub,...> ;Clinical Cancer Research. 2023 Sep 15
• Cross-Study Comparisons of JAK2 Inhibitors in Myelofibrosis: Risks and Recommendations.
  John Mascarenhas, Ruben Mesa> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Oct 1
• 1 citations
  Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.
  Ruben Mesa, Srdan Verstovsek, Uwe Platzbecker, Vikas Gupta, David Lavie, Pilar Giraldo, Christian Recher, Jean-Jacques Kiladjian, Stephen T Oh, Aaron T Gerds, Timothy ...> ;Haematologica. 2024 Feb 1
• 5 citations
  The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Feasibility Phase.
  Mendez Luque, L., Avelar-Barragan, J., Nguyen, H., Nguyen, J., Soyfer, E., Liu, J., Chen, J., Mehrotra, N., Kosiorek, H., Dueck, A., Himstead, A., Heide, E., Lem, M., ...> ;Medrxiv. 2023 May 12
• 8 citations
  Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
  Srdan Verstovsek, Ruben Mesa, Vikas Gupta, David Lavie, Viviane Dubruille, Nathalie Cambier, Uwe Platzbecker, Marek Hus, Blanca Xicoy, Stephen T Oh, Jean-Jacques Kilad...> ;Blood Advances. 2023 Jul 25
• 2 citations
  Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.
  Raoul Tibes, Heidi E Kosiorek, Amylou C Dueck, Jeanne Palmer, Lisa Sproat, James Bogenberger, Shahrukh Hashmi, Ruben Mesa, William Hogan, Mark R Litzow, Aref Al-Kali> ;Cancer. 2023 Aug 1
• 3 citations
  PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis.
  Tamara K Moyo, Ashwin Kishtagari, Matthew T Villaume, Brandon McMahon, Sanjay R Mohan, Tess Stopczynski, Sheau-Chiann Chen, Run Fan, Yuankai Huo, Hyeonsoo Moon, Yuchen...> ;Clinical Cancer Research. 2023 Jul 5
• Sepsis-Related Outcomes of Patients with Philadelphia-Negative Myeloproliferative Neoplasms.
  Luis F Gonzalez-Mosquera, Bernard Moscoso, Pool Tobar, Diana Cardenas-Maldonado, Alida I Podrumar, Ruben Mesa, Cuenca, J., John A Cuenca> ;Cancer Investigation. 2023 May 1
• Sepsis-related outcomes of patients with Philadelphia-negative myeloproliferative neoplasms.
  Luis F Gonzalez-Mosquera, Bernard Moscoso, Pool Tobar, Diana Cardenas-Maldonado, Alida I Podrumar, Ruben Mesa, John A Cuenca> ;Cancer Investigation. 2023 Mar 2
• 4 citations
  Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.
  Srdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M Vannucchi, Ruben A Mesa, Peg Squier, J E Hamer-Maansson, Claire Harrison> ;Cancer. 2023 Jun 1
• 3 citations
  New Treatments for Myelofibrosis.
  Douglas Tremblay, Ruben Mesa> ;Current Treatment Options in Oncology. 2023 Feb 1
• 34 citations
  Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phas...
  Srdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew T Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mi...> ;Lancet. 2023 Jan 28
• Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis.
  Claire Harrison, Abdulraheem Yacoub, Bart Scott, Adam Mead, Aaron T Gerds, Jean-Jacques Kiladjian, Ruben Mesa, Miklos Egyed, Christof Scheid, Valentin Garcia Gutierrez...> ;Haematologica. 2023 Jul 1
• 1 citations
  Childhood cancer survival in the highly vulnerable population of South Texas: A cohort study.
  Shenghui Wu, Yanning Liu, Melanie Williams, Christine Aguilar, Amelie G Ramirez, Ruben Mesa, Gail E Tomlinson> ;Plos One. 2023 Jan 1
• 2 citations
  Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib.
  Abdulraheem Yacoub, Ruben A Mesa, Stephen T Oh> ;JCO Precision Oncology. 2023 Jan 1
• Join now to see all

Abstracts/Posters

• Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia
  Ruben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database
  Ruben A. Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Patient-Reported Outcomes (PRO) Data from Patients (Pts) with Essential Thrombocythemia (ET) Enrolled in the MOST Study
  Ruben A. Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Set...
  Ruben A. Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
  Ruben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolit...
  Ruben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermedi...
  Ruben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Standardized Equation Model of Quality of Life in Myeloproliferative Neoplasms
  Ruben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• SOHO 2020: Bringing 'MPN Awareness' to Hematology Community 
  Mayo School of Continuous Professional Development, Phoenix, Arizona - 9/14/2013
• Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor_Na¥ve Myelofibrosis Patients Treated with Momelo... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Proposal of an endpoint for a phase III clinical study of essential thrombocythemia: Balancing between short term effects and long term benefits. 
  2019 ASCO Annual Meeting - 6/1/2019
• As If Myeloproliferative Neoplasms Weren't Already Challenging Enough 
  60th American Society of Hematology Annual Meeting - 12/2/2018
• Social Media for the Hematologist: Today and in the Future 
  60th American Society of Hematology Annual Meeting - 12/2/2018
• Characteristics Associated with Hydroxyurea Treatment Change in Patients with Polycythemia Vera: An Analysis from the Reveal Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Correlation between MPN-SAF TSS and EORTC QLQ-C30 Scores in Patients with PV: Data from the Reveal StudyClinically Relevant Abstract 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United StatesClinically Relevant Abstract 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• As If Myeloproliferative Neoplasms Weren't Already Challenging Enough 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Social Media for the Hematologist: Today and in the Future 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intole... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A phase 2, multicenter, open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and ane... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all